Bristol Myers Squibb Non-GAAP EPS of $1.83 Beats by $0.03, Revenue of $12B in-line
Seeking Alpha2022-02-04
- Bristol Myers Squibbpress release(NYSE:BMY): Q4 Non-GAAP EPS of $1.83beats by $0.03.
- Revenue of $12B (+8.1% Y/Y) in-line.
- Revenue breakdown:Eliquis of $2.67B vs. $2.41B in 3Q21; Opdivo of $1.99B vs. $1.91B in 3Q21; Revlimid of $3.33B vs. $3.35B in 3Q21.
- Announces $15 Billion Share Repurchase Authorization; $5 Billion Accelerated Share Repurchase Agreement to be Executed During the First Quarter 2022
- Bristol Myers Squibb is introducing its 2022 GAAP EPS guidance range of $3.37 - $3.67 and reaffirming its non-GAAP EPS guidance range of $7.65 - $7.95
免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。